Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
- Sponsor
- Region Örebro County
- Study ID
- NCT03983018
- Phase
- PHASE2
- Status
- Completed
Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders
- Treatment-resistant Schizophrenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUGInfusion
Study Details
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.
Key Dates
- Start date
- Aug 7, 2019
- Status verified
- Jan 2025
- Primary completion
- Mar 31, 2022
- Completion
- Mar 31, 2022
Study Design
- Enrollment
- 9 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Rituximab1000 mg of rituximab, infusion once
Primary Outcome Measure
Positive and Negative Syndrome Scale (PANSS) [ Time Frame: week 20 ]
Related Studies
- Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory HallucinationsRecruiting · Boston VA Research Institute, Inc. · Brockton, Massachusetts
- Biomarkers/Biotypes, Course of Early Psychosis and Specialty ServicesRecruiting · Beth Israel Deaconess Medical Center · Hartford, Connecticut
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaPHASE3 · Recruiting · Newron Pharmaceuticals SPA · Los Angeles, California